Revision 1		
Livin (D61D1) XP [®] Rabbit mAb		Il Signaling CHNOLOGY®
Store	Orders:	877-616-CELL (2355) orders@cellsignal.com
	Support:	877-678-TECH (8324)
#5471	Web:	info@cellsignal.com cellsignal.com
#	3 Trask Lane Danvers Massa	chusetts 01923 USA

For Research Use Only.	Not for Use in Diac	nostic Procedures.
------------------------	---------------------	--------------------

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene I
W, IP, IF-IC Product Usage Information	н	Endogenous Application Western Blotting Immunoprecipitation Immunofluorescence	34, 36 (Immunocytochem	Rabbit IgG	#Q96CA5	79444 Dilution 1:1000 1:200 1:800
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
Specificity/Sen	sitivity	Livin (D61D1) XP [®] Rab	bit mAb detects en	dogenous levels of total	livin protein.	
Source / Purific	cation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala195 of human livin protein.				
		Överexpression of IAF tumors suggests an ir proteins function thro caspase-3, caspase-7, mitochondrial protein and activation of the o Livin (BIRC7/ML-IAP) is RING finger motif that localized in the nucleu a 298 amino acid isofo apoptotic stimuli (8). I degradation of the pri preferential expressio	P family members, p nportant role for th ugh direct interacti and caspase-9 (5,6) Smac blocks their i caspase (2). s a potent anti-apop t is highly expressed is and diffusely in th orm (α) and a 280 an n addition to direct p-apoptotic protein	Jde c-IAP1, c-IAP2, XIAP, particularly survivin and 1 ese proteins in cancer p ons to inhibit the activity. In addition, binding of nteraction with caspase btotic IAP family membe d in human melanomas he cytoplasm (5). The livi mino acid form (β), with ly inhibiting caspase acti Smac through the ubiqu	livin, in cancer cell rogression (3-5). In / of several caspase IAP family membe -9, thereby allowing r containing a sing and absent in norm n gene encodes tw different biological vity, livin can prom	lines and primary general, the IAP es, including rs to the g the processing le BIR domain and nal tissues (5,7). It ro splicing variants l activity to various lote the
			s, has led to studie	s analyzing the use of liv		regulation of livin
Background Re	eferences	1. Deveraux, Q.L. and 2. Deveraux, Q.L. et al 3. Altieri, D.C. et al. (19 4. Tamm, I. et al. (2000	is, has led to studie Reed, J.C. (1999) <i>Ge</i> (1998) <i>EMBO J</i> 17, 999) <i>Lab Invest</i> 79, 1 0) <i>Clin Cancer Res</i> 6 mes, B.C. (2001) <i>J Bi</i> (1997) <i>Nature</i> 388, 9) <i>Curr Biol</i> 10, 1359 01) <i>FEBS Lett</i> 495, 5 <i>Cell Death Differ</i> 13,	s analyzing the use of liv nes Dev 13, 239-52. 2215-23. 327-33. , 1796-803. ol Chem 276, 3238-46. 300-4. -66. 6-60. 2079-88.		regulation of livin
		1. Deveraux, Q.L. and 2. Deveraux, Q.L. et al 3. Altieri, D.C. et al. (19 4. Tamm, I. et al. (2000 5. Kasof, G.M. and Goi 6. Deveraux, Q.L. et al 7. Vucic, D. et al. (200 8. Ashhab, Y. et al. (200 9. Ma, L. et al. (2007) 10. Liu, B. et al. (2007)	is, has led to studie Reed, J.C. (1999) <i>Ge</i> (1998) <i>EMBO J</i> 17, 199) <i>Lab Invest</i> 79, 1 (197) <i>Lab Invest</i> 79, 1 (197) <i>Nature</i> 388, (1997) <i>Nature</i> 388, (197) <i>Nature</i> 388, (197) <i>Curr Biol</i> 10, 1359 (1) <i>FEBS Lett</i> 495, 5 <i>Cell Death Differ</i> 13, <i>Cancer Lett</i> 250, 16	s analyzing the use of liv nes Dev 13, 239-52. 2215-23. 327-33. , 1796-803. ol Chem 276, 3238-46. 300-4. -66. 6-60. 2079-88.	in in cancer therap	nregulation of livin y (10).
Background Re Species Reactiv Western Blot B	/ity	1. Deveraux, Q.L. and 2. Deveraux, Q.L. et al 3. Altieri, D.C. et al. (19 4. Tamm, I. et al. (2000 5. Kasof, G.M. and Goi 6. Deveraux, Q.L. et al 7. Vucic, D. et al. (2000 8. Ashhab, Y. et al. (2006) 9. Ma, L. et al. (2007) 10. Liu, B. et al. (2007) Species reactivity is de	is, has led to studie Reed, J.C. (1999) <i>Ge</i> (1998) <i>EMBO J</i> 17, 199) <i>Lab Invest</i> 79, 1 <i>Offin Cancer Res</i> 6 mes, B.C. (2001) <i>J Bi</i> (1997) <i>Nature</i> 388 <i>Curr Biol</i> 10, 1359 01) <i>FEBS Lett</i> 495, 5 <i>Cell Death Differ</i> 13, <i>Cancer Lett</i> 250, 16 etermined by testing ern blots, incubate	s analyzing the use of liv <i>nes Dev</i> 13, 239-52. 2215-23. 327-33. 1796-803. <i>ol Chem</i> 276, 3238-46. 300-4. -66. 6-60. 2079-88. 58-76. g in at least one approve membrane with diluted	in in cancer therap	vregulation of livin y (10). western blot).
Species Reactiv	<i>v</i> ity uffer	1. Deveraux, Q.L. and 2. Deveraux, Q.L. et al 3. Altieri, D.C. et al. (19 4. Tamm, I. et al. (2000 5. Kasof, G.M. and Go 6. Deveraux, Q.L. et al 7. Vucic, D. et al. (2000 8. Ashhab, Y. et al. (2006) 8. Ashhab, Y. et al. (2006) 10. Liu, B. et al. (2007) Species reactivity is de IMPORTANT: For west TBS, 0.1% Tween® 20	is, has led to studie Reed, J.C. (1999) <i>Ge</i> (1998) <i>EMBO J</i> 17, 199) <i>Lab Invest</i> 79, 1 1) <i>Clin Cancer Res</i> 6 mes, B.C. (2001) <i>J Bi</i> (1997) <i>Nature</i> 388, 1) <i>Curr Biol</i> 10, 1359 01) <i>FEBS Lett</i> 495, 5 <i>Cell Death Differ</i> 13, <i>Cancer Lett</i> 250, 16 etermined by testing etermined by testing etermined by testing etermined by testing	s analyzing the use of liv <i>nes Dev</i> 13, 239-52. 2215-23. 327-33. 1796-803. <i>ol Chem</i> 276, 3238-46. 300-4. -66. 6-60. 2079-88. 58-76. g in at least one approve membrane with diluted	in in cancer therap ed application (e.g., primary antibody i	vregulation of livin y (10). western blot). n 5% w/v BSA, 1X
Species Reactiv	/ity uffer ey	1. Deveraux, Q.L. and 2. Deveraux, Q.L. et al 3. Altieri, D.C. et al. (19 4. Tamm, I. et al. (2000 5. Kasof, G.M. and Go 6. Deveraux, Q.L. et al 7. Vucic, D. et al. (2000 8. Ashhab, Y. et al. (2006) 8. Ashhab, Y. et al. (2006) 10. Liu, B. et al. (2007) Species reactivity is de IMPORTANT: For west TBS, 0.1% Tween® 20	is, has led to studie Reed, J.C. (1999) <i>Ge</i> (1998) <i>EMBO J</i> 17, 199) <i>Lab Invest</i> 79, 1 1) <i>Clin Cancer Res</i> 6 mes, B.C. (2001) <i>J Bi</i> (1997) <i>Nature</i> 388, 1) <i>Curr Biol</i> 10, 1359 01) <i>FEBS Lett</i> 495, 5 <i>Cell Death Differ</i> 13, <i>Cancer Lett</i> 250, 16 etermined by testing etermined by testing etermined by testing etermined by testing	s analyzing the use of liv nes Dev 13, 239-52. 2215-23. 327-33. 1796-803. <i>ol Chem</i> 276, 3238-46. 300-4. -66. 6-60. 2079-88. 38-76. g in at least one approve membrane with diluted shaking, overnight.	in in cancer therap ed application (e.g., primary antibody i	vregulation of livin y (10). western blot). n 5% w/v BSA, 1X

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information. Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's **Limited Uses** terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect. Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

Orders: 877-616-CELL (2355) • orders@cellsignal.com • Support: 877-678-TECH (8324) • info@cellsignal.com • Web: cellsignal.com For Research Use Only. Not for Use in Diagnostic Procedures.